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Abstract 76 
 77 
Introduction 78 
 79 
The 7-valent pneumococcal conjugate vaccine (Prevenar®, Wyeth; PCV7) was 80 
introduced to the UK paediatric immunisation schedule in 2006. This study 81 
investigates trends in serotypes and multi locus sequence types (STs) among cases of 82 
invasive pneumococcal disease (IPD) in Scotland prior to, and following, the 83 
introduction of PCV7. 84 
 85 
Methods 86 
 87 
Scottish Invasive Pneumococcal Disease Enhanced Surveillance has records of all 88 
cases of invasive pneumococcal disease in Scotland since 1999. Cases diagnosed from 89 
blood or cerebrospinal fluid isolates until 2010 were analysed. Logistic and poisson 90 
regression modelling was used to assess trends prior to and following the introduction 91 
of PCV7. 92 
 93 
Results  94 
 95 
Prior to PCV7 use, on average 650 cases of IPD were reported each year; 12% 96 
occurred in those aged <5 years and 35% affected those aged over 65 years. Serotypes 97 
in PCV7 represented 47% of cases (68% in <5 year olds). The serotype and ST 98 
distribution was relatively stable with only serotype 1 and associated ST 306 showing 99 
an increasing trend. PCV7 introduction was associated with a 69% (95% CI: 50%, 100 
80%) reduction in the incidence of IPD among those aged <5 years, a 57% (95% CI: 101 
47%, 66%) reduction among those aged 5-64 years but no significant change among 102 
those aged 65 years and over where increases in non-PCV7 serotypes were observed. 103 
Serotypes which became more prevalent post-PCV7 are those which were associated 104 
with STs related to the PCV7 serotypes.   105 
 106 
 107 
 108 
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Conclusions 109 
 110 
Routine serotyping and sequence typing in Scotland allowed the assessment of the 111 
relationship between the capsule and the clones in the post vaccination era. Changes 112 
in the distribution of serotypes post PCV7 introduction appear to be driven by 113 
associations between serotypes and STs prior to  PCV7 introduction. This has 114 
implications for the possible effects of the introduction of higher valency vaccines and 115 
could aid in predicting replacement serotypes in IPD 116 
 117 
6 
 
Introduction 118 
 119 
Streptococcus pneumoniae (S. pneumoniae) is responsible for a substantial burden of 120 
disease, accounting for an estimated 1.6 million deaths annually worldwide [1]. In 121 
developed countries, the observed incidence of invasive pneumococcal disease (IPD) 122 
is between 8 and 75 cases per 100,000 individuals [2], with studies showing that the 123 
burden of disease is predominantly attributable to only around 20 or 30 of the 941 124 
circulating pneumococcal serotypes [3]. Furthermore, it has been observed that 125 
approximately two thirds of adult pneumococcal disease and 80% of disease in 126 
children is attributable to between only around 8 to 10 serotypes [4]. 127 
 128 
Many recent studies of serotypes involved in IPD concern the comparison of a pre-129 
conjugate vaccination period to a post-vaccination period to examine any changes in 130 
serotype distribution likely to be related to the use of the 7-valent pneumococcal 131 
conjugate vaccine (PCV7). In the USA, and other countries subsequently, great 132 
reductions in IPD were documented which were not limited to the vaccine targeted 133 
age group [5]. However, increases in IPD caused by non-PCV7 serotypes, in 134 
particular serotype 19A, following PCV7 use have been documented [5-11]. 135 
 136 
The capsule is thought to be the main determinant for carriage prevalence and 137 
invasiveness of the pneumococcus and hence the determinant of prevalence amongst 138 
invasive disease isolates before and after vaccination [12, 13]. However, concerns 139 
have been raised that the increase in serotype 19A IPD in particular is perhaps 140 
attributable to a capsular switch event after being found associated with a sequence 141 
type (ST), ST695, which was previously only linked with vaccine serotype 4 [14, 15]. 142 
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Other studies have documented increases due to the expansion of multi-drug resistant 143 
STs such as ST276 and ST320 [16, 17]. Thus, it is becoming increasingly important 144 
to examine both the STs and serotypes involved in IPD in order to determine the 145 
potential effectiveness of serotype-specific pneumococcal vaccinations. 146 
 147 
In September 2006, PCV7 was introduced to the routine childhood immunisation 148 
schedule in the United Kingdom in a three dose program at age 2, 4, and 13 months, 149 
with a catch-up for those aged up to 2 years. This study examines the trends in 150 
serotype and ST distributions prior to the introduction of PCV7 in Scotland, adding to 151 
existing reports on the pre-vaccine period in Scotland which describe increases in 152 
serotype 1 and ST 306 [18, 19]; the effect of PCV7 on the incidence of IPD; trends in 153 
the serotype and ST distribution post-vaccination; and the association between 154 
serotype and ST pre- and post-vaccination. 155 
 156 
Methods 157 
 158 
Data 159 
 160 
Data were obtained from the Scottish Invasive Pneumococcal Disease Enhanced 161 
Surveillance (SPIDER) database on all cases of IPD, identified by blood or 162 
cerebrospinal fluid, in Scotland between 1999 and 2010. The serogroup responsible 163 
for each case of disease was available for all years, whilst serotype and ST 164 
information was only available from 2002. 165 
 166 
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Clinical isolates (grown from blood or cerebrospinal fluid) of S. pneumoniae were 167 
sent to Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus 168 
Reference Laboratory (SHLMPRL) after identification at diagnostic microbiology 169 
laboratories in Scotland. At SHLMPRL, these isolates were grown on Columbia 170 
blood agar (Oxoid, United Kingdom) at 37oC under anaerobic conditions by use of an 171 
anaerobic pack (Oxoid, United Kingdom) and after a single subculture were stored at 172 
-80oC on Protect beads (M-Tech Diagnostics, United Kingdom). Isolates were 173 
serotyped by a coagglutination method described elsewhere [20]. MLST was 174 
performed as described previously [21-23].  175 
 176 
Epidemiological years ranging from winter of one year to the end of autumn of the 177 
following year were used to ensure winter seasons were grouped together since IPD 178 
predominantly occurs during this season. 179 
 180 
Serotypes and STs were classified according to their joint occurrence prior to the 181 
introduction of PCV7 (1999-2005) and their emergence post-PCV7 (2006-2010). STs 182 
were classified as associated with PCV7 serotypes if they occurred at least once in 183 
conjunction with one of the seven PCV7 serotypes (labelled PCV7-ST); otherwise 184 
they were classified as not associated with PCV7 serotypes (NonPCV7-ST). STs 185 
which only occurred following the introduction of PCV7 were classified separately as 186 
PostPCV7-ST. The PCV7-ST group was subdivided into two groups: a group of 12 187 
STs (9, 36, 113, 124, 138, 156, 162, 176, 205, 206, 246, 311) with a high frequency of 188 
co-occurrence with the PCV7 serotypes (labelled HF PCV7-ST), and a larger group 189 
with low frequency co-occurrence (LF PCV7-ST). Serotypes were categorised in four 190 
different groups: PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 23F); serotypes not in 191 
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PCV7 but associated with STs linked through co-occurrence prior to the PCV7 192 
serotypes, denoted PCV7-ST serotypes; serotypes not in PCV7 and not associated 193 
with the STs linked to PCV7 serotypes, denoted NonPCV7-ST serotypes; and 194 
serotypes which only occurred post-PCV7 vaccination, denoted PostPCV7 serotypes. 195 
 196 
Statistical analysis 197 
 198 
Logistic regression models were used to examine changes and linear trends in the 199 
serogroup, serotype and ST distributions, with year treated as a continuous variable 200 
ranging from 1999 to 2005. Only serogroups, serotypes and STs responsible for at 201 
least 1% of cases of IPD were considered. Analyses were carried out for the 202 
serogroups for age groups 0-4, 5-64, and  \HDUV VHSDUDWHO\ %RQIHUURQL DGMXVWHG203 
confidence intervals were calculated and the Benjamini and Hochberg adjustment for 204 
multiple testing used in the assessment of the significance of the linear trend [24]. 205 
 206 
Poisson regression models were used to assess changes in IPD incidence. The 207 
percentage change in the incidence of PCV7 serotypes and NonPCV7 serotypes from 208 
the pre-vaccine period to the post-vaccine period was assessed by predicting the post-209 
vaccination incidence allowing for a trend in the pre-vaccination years and comparing 210 
the observed cases with the predicted as suggested elsewhere [25, 26]; 95% 211 
confidence intervals were used. Cases with missing age (27, 0.4%) were omitted. For 212 
637 cases (10.1%), no information on the serotype or serogroup was available. The 213 
number of vaccine type (VT) or non-vaccine type (NVT) serotypes was imputed, 214 
separately by year and age group, using the observed proportions of VT serotypes. 215 
Imputation of serotype, from serogroup, was also carried out when serotype 216 
Comment [KL1]: Should I add further 
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information was not available prior to 2002. This was based upon the observed 217 
proportions of serotypes within serogroups in the period 2002-2006, separately by age 218 
group. All analysis was carried out using R versions 2.8-2.12 [27]. 219 
 220 
 221 
Results 222 
 223 
Trends in the serotype and sequence type distributions prior to the introduction on 224 
PCV7 225 
 226 
Between 1999/00 and 2005/06, on average approximately 650 cases of IPD per year 227 
were reported in Scotland, rising from 538 in 1999/00 to 743 in 2002/03. A 228 
suEVHTXHQW GURS RFFXUUHG SULPDULO\ DPRQJVW WKRVH DJHG  \HDUV IROORZLQJ WKH229 
introduction of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in the 230 
UK for those aged at least 65 years in 2003, with a coverage of ?., This was followed 231 
by a rise to 739 in 2005/06. IPD was most common amongst the elderly during this 232 
SHULRGZLWKRIDOOFDVHVRI,3'LGHQWLILHGLQWKRVHDJHG\HDUVRIFDVHV233 
affected those aged <5 years. 234 
 235 
Serogroup analysis 236 
 237 
In total, 36 different serogroups were identified in IPD between 1999/00 and 2005/06. 238 
Serogroup 14 was the most common, accounting for approximately 17% of all cases. 239 
Serogroups 9 and 1 were also common, causing around 9% and 8% of cases, 240 
respectively. Serogroup 1 replaced serogroup 14 as the most common serogroup in 241 
Comment [KL2]: Stefan/Chris- any idea 
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2005/06. The proportion of IPD cases associated with serogroup 1 increased steadily 242 
over the pre-PCV7 study period. 243 
 244 
There wais significant evidence of an increasing trend for serogroup 1 (p<0.001), 245 
(Table 1, Part A). Serogroup 14 wais borderline significant in the analysis for all age 246 
groups after adjustment for multiple testing, with a decreasing trend between 1999/00 247 
and 2005/06.  248 
Serotype analysis 249 
 250 
Between 2003/04 and 2005/06, 42 different serotypes were identified as causing IPD. 251 
PCV7 serotypes accounted for 47% of cases in this period and were responsible for 252 
68% of cases in those <5 years, 40% in those aged 5-64 years and LQWKRVH253 
years. The most common serotypes, 14 (15%), 1 (13%), 4 (7%), 9V (7%), 8 (6%), 3 254 
(6%), 23F (5%), 6B (4%), 7F (4%) and 19F (4%), together account for 71% of IPD.  255 
 256 
A statistically significant increasing trend in the distribution of IPD isolates was found 257 
in the unadjusted test for serotype 1 IPD (p=0.029). However, no other serotypes were 258 
found to have significant increasing or decreasing trends. 259 
 260 
Sequence type analysis 261 
 262 
The most common STs in IPD between 2003/04 and 2005/06 were 9 (9%), 306 (9%), 263 
162 (6%), 53 (5%), 180 (4%), 191 (4%), 124 (4%), 218 (3%), 199 (3%) and 227 264 
(3%). ST9 is commonly associated with serotype 14, with approximately 60% of 265 
serotype 14 IPD during this period identified as ST9 whilst ST306 is commonly 266 
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associated with serotype 1. There were 158 STs were found in IPD in 2003/04, 140 in 267 
2004/05 and only 115 in 2005/06, showing a reduction in the diversity of STs over 268 
time. 269 
 270 
ST306 was found to have a significant increasing trend in the distribution of IPD 271 
isolates between 2003/04 and 2005/06, comparing to the unadjusted significance level 272 
of 0.05 (Table 1, Part A). No other STs showed a significant increasing or decreasing 273 
trend. 274 
 275 
The effect of PCV7 on the incidence of IPD 276 
 277 
Following PCV7 use, the incidence of IPD caused by PCV7 serotypes declined by 278 
97.4% in children aged <5 years (Table 2). Among those aged 5- \HDUV DQG 279 
years, a significant reduction of VT IPD of 86.3% and 80.4%, respectively, was 280 
observed. In those <5 years and those aged 5-64 years, there was no significant 281 
increase in NVT notifications in 2008/09 compared to the predicted incidence (Figure 282 
,QWKHSRSXODWLRQDJHG\HDUVDVLJQLILFDQWLQFUHDVHLQ197GLVHDVHRI283 
was observed. The reduction in VT incidence and increase in NVT incidence resulted 284 
in no change in all-type incidence in this age group. 285 
 286 
Almost all NVT serotypes exhibited an increase in disease incidence from the last two 287 
pre-vaccination years to 2008/09 (7F: 153.6%, 3: 26.2%, 8: 42.5%, 19A: 78.7%, 22F: 288 
151.6%, 6A: 31.8%, 12F: 2.3%, 11A: 73.9%, 9N: 33.3%). The exception is serotype 1 289 
which showed a decrease despite the previously reported increasing trend pre-PCV7. 290 
However, only increases in 7F (128.5%; 95% CI (30%, 308.8%)) and 22F (126.7%; 291 
Comment [KL3]: Remove unadjusted? 
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95% CI (15%, 356.6%)) were found to be significant when allowing for pre-292 
vaccination trends. The significant decrease of serotype 1 after vaccination was 293 
mainly driven by the age groups <5 years and 5-65 years. 294 
 295 
Trends in the serotype and sequence type distribution post vaccination  296 
 297 
Post-PCV7, seven serotypes not previously reported in Scotland were noted- 23B (12 298 
times), 28 (6), 6C (5), 12 (1), 16A (1), 17A (1), and 35C (1), accounting for 27 of 299 
2213 isolates typed. 164 STs which had not previously been reported were noted, 300 
amounting to 222 reports of 2203 isolates sequenced. 10% of the isolates sequenced 301 
were new STs whilst only 1% of the isolates typed gave rise to new serotypes. 302 
 303 
Amongst the 14 serotypes each accounting for at least 1% of IPD cases post-PCV7 304 
(Table 1, Part B), there were significant increasing trends in the distribution amongst 305 
IPD isolates for 19A and 22F and decreasing trends for serotypes 1 and 20. Serotype 1 306 
decreased at a rate of 29% per year and serotype 20 decreased at a rate of 36% per 307 
year. Serotype 19A increased at a rate of 40% per year while 22F increased at a rate 308 
of 34% per year. 309 
 310 
There were 11 STs which accounted for more than 1% of all STs reported among IPD 311 
cases post-PCV7. ST306 decreased significantly at a rate of 37% per year, 312 
comparable with the decrease in its associated serotype 1. ST199 and ST433 both 313 
exhibit significant increases post-PCV7 with 25% and 51% increases per year, 314 
respectively. ST199 is principally associated with serotype 19A and, to a lesser 315 
14 
 
extent, with 15B whilst ST433 is almost universally associated with serotype 22F.  316 
Serotype 20 is principally associated with ST235. 317 
 318 
The association between serotypes and STs pre- and post-vaccination 319 
 320 
The association between serotypes and STs in the period prior to the introduction of 321 
PCV7 is shown in Table 3. PCV7 serotypes are associated with a total of 166 STs, 322 
however only 12 STs (9, 36, 113, 124, 138, 156, 162, 176, 205, 206, 246, 311) 323 
account for the vast majority (74.3%) of the IPD cases. The PCV7 serotypes, 324 
associated with these 12 STs (labelled PCV7-HF PCV7-ST), were responsible for 779 325 
IPD cases. A further 269 cases of IPD were caused by PCV7 serotypes associated 326 
with the remaining 154 STs (labelled PCV7-LF PCV7-ST). In total, 25 serotypes 327 
(named PCV7-ST serotypes) not present in PCV7, were associated with the 166 STs 328 
linked to PCV7 serotypes.  329 
 330 
There are 708 entries in Table 3, of which only 25 are linked with HF PCV7-ST, 12 331 
are high frequency STs associated with PCV7, Regarding serotypes not present in 332 
PCV7, but associated with the 166 STs linked to PCV7, 25 different serotypes were 333 
responsible for 708 IPD cases, of which only 25 were linked with HF PCV7-ST. The 334 
and the other 683 weare associated with the remaining 154 low frequency STs (cross-335 
classification of PCV7-ST serotypes and LF PCV7-ST). The 25 PCV7-ST serotypes 336 
hadve associations (353 cases) with 151 STs which weare not directly associated with 337 
PCV7 (cross-classification of PCV7 ST serotypes and NonPCV7-ST). Finally these 338 
151 NonPCV7-STs weare associated with 22 NonPCV7-ST serotypes (145 cases) 339 
which hadve no direct link with any ST linked to PCV7. 340 
Comment [KL4]: Check number 
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 341 
Trends in the distribution of groups of serotypes and STs are presented in Figure 2 342 
and Figure 3, respectively. Both graphs show a relatively stable distribution in the 343 
pre-PCV7 period. The serotype distribution has changed in favour of those serotypes 344 
which were associated with STs shown to have had an association with serotypes in 345 
the PCV7 vaccine– the PCV7-ST serotypes. Prior to 2006/07, these serotypes formed 346 
~40% of all serotypes but in 2009/10 they formed 80%. The NonPCV7-ST serotypes 347 
formed 6% of serotypes prior to 2006/07 and rose to 8% in 2008/09 and 11% in 348 
2009/10. The ratio of the percentage of NonPCV7-ST serotypes to the percentage of 349 
PCV7-ST serotypes  has remained relatively constant over the whole period.  The ST 350 
distribution has not changed as dramatically but the 12 high frequency STs associated 351 
with the PCV7 serotypes are decreasing while the remaining low frequency STs 352 
associated with PCV7 and the STs not associated with PCV7 have increased by about 353 
10% each. New post PCV7 STs account for ~10% of STs in 2009-10. 354 
 355 
Discussion 356 
 357 
Prior to the introduction of PCV7, the distribution of serotypes and STs among 358 
Scottish IPD cases was fairly static, only the proportion of serotype 1 was found to 359 
significantly increase, along with a corresponding increase in ST306, among IPD 360 
cases. Introduction of routine vaccination with PCV7 drastically reduced the burden 361 
of VT IPD in Scotland not only among children targeted for vaccination but also for 362 
the rest of the population. Little evidence of serotype replacement was found except 363 
for the elderly where the increase in NVT IPD outbalanced the decrease in VT IPD. 364 
The major replacement serotypes were 19A and 22F along with the STs 199 and 433. 365 
Field Code Changed
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The routine collection of information for both the genetic background and the 366 
expressed capsular serotype further allowed an analysis of the relationship in response 367 
to vaccine implementation. Interestingly, the proportional increase of serotypes after 368 
vaccination was greatly attributable mostly confined to those serotypes which are 369 
associated with PCV7 STs. 370 
 371 
One of the key strengths of this study is that the IPD data for Scotland can be 372 
considered as a complete national data set as more than 90% of pneumococci 373 
isolated from IPD patients in Scotland are sent to the SHLMPRL [28]. Our use of 374 
logistic and poisson regression to model linear trends in the serotype and ST 375 
distribution enables the identification of changes in the serotype epidemiology. 376 
Our findings on pre and post-vaccination trends of specific serotypes and STs mainly 377 
correspond to existing literature. In particular the distribution of serotypes and STs in 378 
Scotland prior to the introduction of PCV7 has similarly been reported by Jefferies et 379 
al. [18]. Also serotype 1 bacteraemia was found to increase over time in the UK and 380 
Ireland [29] as well as serotype 1 associated IPD in England and Wales [25]. 381 
Furthermore, the increase we observe amongst the proportion of serotype 19A has 382 
been widely observed [14-17, 30-32].  383 
 384 
Within four years following PCV7 use, VT serotypes were almost eliminated from 385 
IPD cases in those aged <5 years, providing clear evidence of a strong vaccine effect 386 
in the targeted age group, as has been documented in other countries [33-35]. In 387 
addition, there appears to be evidence of herd protection in those aged 5-64 years, as 388 
well as those aged 65 years. This corresponds with herd protection observed 389 
elsewhere, with sustained benefits of PCV7 use in preventing VT serotypes recently 390 
Comment [KL5]: This is a bit clumsy. 
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documented [36]. HoZHYHU DPRQJ WKRVH DJHG 65 years, there is evidence of 391 
serotype replacement with an increase in NVT incidence, as was also shown in the 392 
United States and elsewhere [37, 38]. It is possible that serotype replacement in those 393 
aged over 65 years could be attributable to the introduction of PPV23 in this age 394 
group, however, it does not appear that the timing of the observed decline in VT IPD 395 
corresponds with the introduction of PPV. Among those aged <5 years and 5-64 396 
years, the impact of serotype replacement is less clear and is masked by the effect of 397 
serotype 1 which was increasing prior to the introduction of PCV7 and then 398 
decreased. However, even accounting for this, serotype replacement in these age 399 
groups has been less pronounced in Scotland than reported in England and Wales [25] 400 
and elsewhere [39, 40].  It is not clear why the pattern in Scotland is different from 401 
that in England and Wales. A possible reason could be the replacement in the 402 
nasopharynx of Scottish residents by mainly opportunistic NVTs which 403 
predominantly cause invasive diseasHLQWKRVH65 years of age. Studying changes in 404 
nasopharyngeal carriage before and after introduction of PCV7 as done elsewhere [41, 405 
42] could shed more light on this.  406 
 407 
Amongst the non-PCV7 serotypes and the STs not primarily associated with these 408 
serotypes, there is some evidence of a change in the distribution. In particular, as 409 
mentioned, serotype 1 decreased following intervention and was mirrored with a 410 
decrease in the incidence of IPD attributable to ST306. The NVT serotypes, 19A and 411 
22F were both observed to increase in IPD, whilst serotype 20 showed a significant 412 
decreasing trend. Serotypes 19A and 22F are in the group of serotypes (PCV7-ST 413 
serotypes) linked to the low frequency STs associated with PCV7 (LF PCV7-ST) and 414 
this is the group of serotypes which were shown to increase. Serotype 20 is in the 415 
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group of serotypes not linked to PCV7 by STs (Non PCV7-ST serotypes) and as a 416 
whole this group of serotypes is relatively static in comparison with PCV7-ST 417 
serotypes. This implies that there is a possible role of the ST in determining the fitness 418 
of a pneumococcus and that it may be possible to predict the serotypes which are 419 
likely to increase the most as a result of the introduction of increased valency 420 
vaccines. In interpreting these results, however, it is important to note that the STs 421 
linked to the common disease causing serotypes in the developing world do not 422 
necessarily correspond with those in the developed world (for example, outbreaks 423 
attributable to serotype 1 in sub-Saharan Africa have been found to be associated with 424 
ST 618 and 217, not 306 and 227 as in the developed world) [43]. Therefore, the 425 
results presented here may not be applicable worldwide.  426 
 427 
The 13-valent PCV contains the seven serotypes found in PCV7, as well as serotypes 428 
1, 3, 5, 6A, 7F and 19A.  This vaccine was introduced to the paediatric vaccination 429 
schedule in the United Kingdom in 2010 and should aid in the prevention of further 430 
IPD in Scotland, however as there will be serotypes linked to those in PCV13 through 431 
STs associated with PCV13 serotypes, a change in the serotype distribution can 432 
perhaps be anticipated due to an increase in those linked serotypes. It is therefore of 433 
clear importance to continue to monitor the STs, as well as the serotypes, associated 434 
with cases of IPD to aid in determining the potential long-term effectiveness of 435 
serotype-specific vaccine interventions and to guide the development of future 436 
vaccineations. 437 
 438 
 439 
 440 
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 Table 1: Results from A) the logistic regression models of serogroups and STs 586 
responsible for at least 1% of IPD between 1999/00 and 2005/06 and between 587 
2003/04 and 2005/06, respectively; B) the logistic regression models of serotypes and 588 
STs responsible for at least 1% of IPD between 2006/2007 and 2009/2010, examining 589 
evidence of significant trends in the proportion of IPD attributable to each serogroup, 590 
serotype and ST.. 591 
Part A: 
Serogroup Count OR 95% CI p-value     ST Count OR 95% CI p-value 
14 673 0.94 (0.883, 0.997) 0.003     9 213 1.06 (0.804, 1.402) 0.539 
9 364 0.97 (0.892, 1.047) 0.230     306 174 1.40 (1.042, 1.869) 0.001 
1 331 1.36 (1.238, 1.493) <0.001     162 145 1.03 (0.741, 1.432) 0.797 
6 301 0.97 (0.891, 1.057) 0.328     53 126 1.01 (0.700, 1.464) 0.924 
19 290 0.98 (0.900, 1.074) 0.595     180 96 1.01 (0.678, 1.508) 0.939 
4 273 1.04 (0.946, 1.134) 0.284     191 95 1.24 (0.823, 1.875) 0.134 
8 247 0.95 (0.865, 1.044) 0.135     124 85 1.00 (0.658, 1.515) 0.987 
23 242 0.94 (0.858, 1.035) 0.084     218 74 1.24 (0.784, 1.956) 0.183 
3 220 1.00 (0.902, 1.100) 0.917     199 68 0.72 (0.444, 1.151) 0.045 
7 162 1.04 (0.926, 1.167) 0.357     227 63 1.22 (0.750, 1.990) 0.244 
18 158 0.98 (0.876, 1.104) 0.685     311 63 0.92 (0.561, 1.498) 0.615 
12 131 1.04 (0.914, 1.183) 0.400     246 58 0.97 (0.593, 1.601) 0.883 
22 107 0.98 (0.849, 1.125) 0.648     433 48 0.60 (0.314, 1.132) 0.022 
20 83 0.95 (0.808, 1.113) 0.360     205 41 1.21 (0.654, 2.228) 0.386 
33 71 0.94 (0.789, 1.110) 0.285     176 41 1.18 (0.620, 2.237) 0.468 
11 65 0.97 (0.811, 1.160) 0.638     206 40 1.22 (0.652, 2.271) 0.372 
15 51 1.01 (0.829, 1.239) 0.864     113 38 1.02 (0.530, 1.965) 0.930 
              235 35 0.77 (0.390, 1.531) 0.284 
              36 32 1.19 (0.572, 2.475) 0.499 
              138 30 1.16 (0.581, 2.295) 0.552 
              62 30 1.14 (0.531, 2.429) 0.636 
  
Part B:             
65 
 
25 
 
1.63 
 
(0.691, 3.838) 
 
0.106 
 
Serotype Count OR 95% CI p-value     ST Count OR 95% CI p-value 
1 210 0.71 (0.58, 0.86) <0.001     306 139 0.73 (0.58, 0.92) <0.001 
8 162 0.85 (0.68, 1.05) 0.026     191 217 1.16 (0.96, 1.39) 0.026 
7F 240 1.11 (0.93, 1.34) 0.091     53 123 0.90 (0.71, 1.14) 0.195 
3 173 1.00 (0.81, 1.23) 0.997     180 135 1.08 (0.86, 1.35) 0.343 
19A 165 1.40 (1.11, 1.75) <0.001     199 128 1.25 (0.98, 1.58) 0.008 
22F 130 1.34 (1.04, 1.72) <0.001     433 88 1.51 (1.12, 2.04) <0.001 
12F 79 1.10 (0.81, 1.49) 0.372     218 59 1.00 (0.72, 1.40) 0.995 
6A 74 0.86 (0.63, 1.17) 0.161     227 46 0.85 (0.58, 1.25) 0.238 
9N 48 0.90 (0.62, 1.32) 0.434     62 45 1.15 (0.78, 1.69) 0.306 
11A 54 1.08 (0.75, 1.56) 0.514     235 23 0.80 (0.47, 1.36) 0.232 
23 
 
20 35 0.64 (0.40, 1.02) 0.005     65 23 0.74 (0.43, 1.28) 0.119 
33F 43 1.13 (0.75, 1.70) 0.397               
15B 31 1.16 (0.72, 1.89) 0.362               
23A 28 0.96 (0.58, 1.57) 0.800               
 592 
 593 
Note:  Count is the number of serogroups and STs among IPD cases in the pre-PCV7 594 
period in Part A and serotypes and STs among IPD cases in the post-PCV7 period in 595 
Part B; OR – Odds Ratio associated with a one year change; CI- 95% Bonferroni 596 
adjusted confidence interval; p-value is the unadjusted p-value. The entries in bold 597 
typeface are those with p-values below the Benjamini and Hochberg adjusted p-value. 598 
24 
 
 599 
Table 2: Incidence rates of the most common non-vaccine type (NVT) IPD serotypes 600 
and vaccine type (VT) serotypes in Scotland from 2004/05 to 2009/10. 601 
 602 
  
Incidence 
2004/05 
 
Incidence 
2005/06 
 
Incidence 
2009/10 
Change 2009/10 
predicted compared 
to observed 
Change 2009/10 
predicted compared 
to observed  
(serotype 1 
excluded) 
0-4 
years  
     
All 38.23 27.35 14.18 -68.5% (-80.4, -50.0) -69.8% (-81.7, -50.8) 
NVT 12.87 7.12 13.49 -39.6% (-71.4, 28.6) -13.4% (-62.4, 102.7) 
VT 25.36 20.24 0.69 -97.4% (-99.6, -91.3) -97.5% (-99.6, -91.4) 
5-64 
years  
     
All 8.11 9.52 6.59 -57.2% (-65.5, -46.9) -42.1% (-54.1, -26.9) 
NVT 4.73 6.22 5.92 -45.6% (-58.3, -29.1) 3.4% (-23.7, 40.3) 
VT 3.38 3.30 0.67 -86.3% (-91.6, -78.4) -87.0% (-92.0, -79.5) 
65+ 
years 
     
All 31.09 32.08 26.48 -4.9% (-24.4, 19.5) 0.0% (-20.7, 26.1) 
NVT 15.06 17.00 24.12 +46.5% (9.0, 97.4) 64.7% (21.4, 124.0) 
VT 16.03 15.08 2.30 -80.4% (-88.6, -67.9) -80.5% (-88.6, -68.0) 
 603 
Notes:  The percentage change is a comparison of the predicted incidence in 2009/10 604 
to the observed incidence in 2009/10 adjusting for the temporal trend pre-vaccination 605 
(see Methods). 95% confidence intervals for the percentage changes are derived from 606 
the Poisson regression model. When serotype 1 is excluded, the percentage changes 607 
for VT differ slightly because inflation in this case is assumed to distribute over all 608 
types. 609 
 610 
 611 
 612 
25 
 
 613 
Table 3: The association between ST and serotype among IPD cases in Scotland in the 614 
period prior to the introduction of PCV7 in September 2006. 615 
 616 
STs not 
associated with 
PCV7 Serotypes
LF PCV7-ST Non PCV7-ST 
9 36 113 124 138 156 162 176 205 206 246 311  [154 STs]  [151 STs]
PNE004 0 0 0 0 0 0 0 0 40 37 56 0
PNE06B 0 0 0 0 25 1 0 37 0 0 0 0
PNE09V 0 0 0 1 0 13 102 0 0 1 0 0
PNE014 208 0 0 84 0 4 1 0 0 0 0 1
PNE18C 0 0 36 0 0 0 0 1 0 0 0 0
PNE19F 1 0 0 0 0 0 35 0 0 0 0 0
PNE23F 0 32 0 0 0 0 0 1 0 0 0 62
PCV7-ST 
serotypes
Serotypes not in 
PCV7 but 
associated with the 
STs linked to PCV7
683 entries 353 entries
NonPCV7-ST 
serotypes
Serotypes not 
associated with any 
ST linked to PCV7
0 145 entries
Serotypes not in PCV7 but associated with the STs linked to PCV7:  
PNE001 PNE003 PNE005 PNE008 PNE020 PNE034 PNE038 PNE06A PNE07A PNE07C PNE07F PNE09A PNE09N PNE11A PNE15A 
PNE15B PNE15C PNE16F PNE17F PNE18B PNE18F PNE19A PNE22F PNE33C PNE33F
Serotypes not associated with any ST linked to PCV7:  
PNE002 PNE013 PNE021 PNE024 PNE027 PNE029 PNE031 PNE037 PNE041 PNE042 PNE10A PNE10F PNE12A PNE12B PNE12F 
PNE18A PNE22A PNE23A PNE24F PNE28F PNE35B PNE35F
STs in the HF PCV7-ST group had more than 10 reports of co-occurrence with PCV7 serotypes.  There are 779 entries for 
these 12 STs.  In the full matrix there are 1048 reports among 166 STs associated with PCV7.
STs associated with PCV7 Serotypes 
269 entries 0
0
25 entries over all serotypes and all 12 sequence types
PCV7 
Serotypes
HF PCV7-ST [12 STs]
 617 
 618 
26 
 
STs not associated 
with PCV7 
Serotypes
LF PCV7-ST Non PCV7-ST 
9 36 113 124 138 156 162 176 205 206 246 311  [154 STs]  [151 STs]
PNE004 0 0 0 0 0 0 0 0 40 37 56 0
PNE06B 0 0 0 0 25 1 0 37 0 0 0 0
PNE09V 0 0 0 1 0 13 102 0 0 1 0 0
PNE014 208 0 0 84 0 4 1 0 0 0 0 1
PNE18C 0 0 36 0 0 0 0 1 0 0 0 0
PNE19F 1 0 0 0 0 0 35 0 0 0 0 0
PNE23F 0 32 0 0 0 0 0 1 0 0 0 62
PCV7-ST 
serotypes
25 Serotypes not in 
PCV7 but associated 
with the STs linked to 
PCV7
683 entries 353 entries
NonPCV7-ST 
serotypes
22 different 
Serotypes not 
associated with any 
ST linked to PCV7
0 145 entries
PCV7 
Serotypes
HF PCV7-ST [12 STs]
STs associated with PCV7 Serotypes 
269 entries 0
0
25 entries over all 25 serotypes and all 12 sequence types
Serotypes not in PCV7 but associated with the STs linked to PCV7:  
PNE001 PNE003 PNE005 PNE008 PNE020 PNE034 PNE038 PNE06A PNE07A PNE07C PNE07F PNE09A PNE09N PNE11A PNE15A PNE15B 
PNE15C PNE16F PNE17F PNE18B PNE18F PNE19A PNE22F PNE33C PNE33F
Serotypes not associated with any ST linked to PCV7:  
PNE002 PNE013 PNE021 PNE024 PNE027 PNE029 PNE031 PNE037 PNE041 PNE042 PNE10A PNE10F PNE12A PNE12B PNE12F PNE18A 
PNE22A PNE23A PNE24F PNE28F PNE35B PNE35F
STs in the HF PCV7-ST group had more than 10 reports of co-occurrence with PCV7 serotypes.  There are 779 entries for these 12 STs.  
In the full matrix there are 1048 reports among 166 STs associated with PCV7.
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27 
 
Figure 1:  Incidence rates of vaccine type (VT) and non-vaccine type (NVT) IPD in 628 
Scotland, by age group. 629 
 630 
28 
 
 631 
Note: All serotypes are included in the left hand column of graphs while serotype 1 is 632 
excluded from the right hand column of graphs. The top row are for those aged 0-4 633 
years, the middle row for those aged 5-64 years and the bottom row for those aged 634 
65+ years. The grey vertical bar denotes the introduction of PCV7. For those aged 635 
65+ years, the first grey vertical bar denotes the introduction of PPV23. The data are 636 
plotted as crosses, the dashed lines show the predicted post vaccination incidence 637 
based on pre vaccination trends and the predicted values from the poisson regression 638 
model are the points joined by the lines. 639 
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Figure 2:  Trends in the serotype distribution from 1999/2000 to 2009/2010. 663 
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 664 
Note: In the period 1999-2002 when only serogroup was available, the serotypes of 665 
PCV7 serogroups were imputed based upon the distribution of serotypes within 666 
serogroups in the period 2003-2006. A sensitivity analysis showed that this had 667 
minimal impact on the distributions presented.  668 
PCV7 – serotypes in the PCV7 vaccine. 669 
PCV7 serotypes – serotypes in the PCV7 vaccine. 670 
PCV7-ST serotypes – serotypes not in the PCV7 vaccine but which are associated 671 
with STs associated with the PCV7 serotypes. 672 
NonPCV7-ST serotypes – the remaining serotypes present among IPD cases prior to 673 
the introduction of PCV7. These serotypes are not associated with any ST connected 674 
with the 7 PCV7 serotypes. 675 
Post PCV7 serotypes – serotypes which have emerged post PCV7 (post September 676 
2006). 677 
 678 
 679 
 680 
 681 
Figure 3:  Trends in the ST distribution from 2002/2003 to 2009/2010. 682 
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Note: HF PCV7-STMain PCV7 – The 12 STs with a strong association with the 685 
PCV7 serotypes in the PCV7 vaccine. LF PCV7-STRest PCV7 – The remaining STs 686 
associated with the PCV7 vaccine serotypes. NonPCV7-ST - STs not associated with 687 
any serotype in the PCV7 vaccine. 688 
Post PCV7 – STs which have emerged post PCV7 (post September 2006). 689 
 690 
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